

LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Material	DayseeTM [Levonorgestrel and Ethinyl Estradiol Tablets (0.15 mg/0.03 mg) and ethinyl estradiol tablets (0.01 mg)]
Manufacturer	Lupin Limited Pithampur (M.P.) – 454 775 INDIA.
Distributor	Lupin Pharmaceuticals, Inc. Naples, FL 34108 United States.

Section 2: Hazard(s) Identification

Fire and Explosion

Expected to be non-combustible.

Health

Do not prescribe Daysee to women who are known to have the following:

- A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:
 - Smoke, if over age 35.
 - Have deep vein thrombosis or pulmonary embolism, now or in the past.
 - Have cerebrovascular disease.
 - Have coronary artery disease.
 - Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation).
 - Have inherited or acquired hypercoagulopathies.
 - Have uncontrolled hypertension.
 - Have diabetes with vascular disease.
 - Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35.
- Undiagnosed abnormal genital bleeding.
- Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past.
- Liver tumors, benign or malignant, or liver disease.
- Pregnancy, because there is no reason to use COCs during pregnancy.

Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations.

Environment

No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Ingredients	CAS No.	Ingredients	CAS No.
Levonorgestrel USP	797-63-7	Methylene Chloride NF	75-09-2
Ethinyl Estradiol USP	57-63-6	Croscarmellose Sodium NF	74811-65-7
Lactose Anhydrous NFC	63-42-3	Magnesium Stearate NF	557-04-0
Microcrystalline Cellulose NF	9004-34-6	Opadry Blue 03B80827	9004-65-3
Povidone USP	9003-39-8	Purified Water USP	7732-18-5
Polacrillin Potassium NF	25212-88-8	Opadry Yellow 13B82555	9004-65-3

* The exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: First-Aid Measures

Ingestion

If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation

Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact

Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact

Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGE

There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.

Section 5: Fire-Fighting Measures

Fire and Explosion Hazards	Assume that this product is capable of sustaining combustion.
Extinguishing Media	Water spray, carbon dioxide, dry chemical powder or appropriate foam.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.
Hazardous Combustion Products	Hazardous combustion or decomposition products are expected when the product is exposed to fire.

Section 6: Accidental Release Measures

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labeled container for recovery or disposal.

Section 7: Handling and Storage

Handling	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
Storage	Store at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature].

Section 8: Exposure Controls/Personal Protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Physical Form

Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)] is available in Extended-Cycle blister card each containing a 13-week supply of tablets: 84 light blue tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and 7 mustard tablets, each containing 0.01 mg of ethinyl estradiol. The light blue tablets are round, biconvex, film-coated tablets, debossed with "LU" on one side, and "V21" on the other side. The mustard tablets are round, biconvex, film-coated tablets debossed with "LU" on one side and "V22" on the other side.

They are supplied as follows:

Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)] is available in an extended cycle blister card of 91 tablets which is packed in a pouch (NDC 68180-846-71). Such two pouches are packed in a carton (NDC 68180-846-73).

Section 10: Stability and Reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Carcinoma of the Breast and Cervix

Women who currently have or have had breast cancer should not use Daysee because breast cancer may be hormonally sensitive.

There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.

Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings are due to differences in sexual behavior and other factors.

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A

IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

DOT - Not Regulated

DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.